欢迎访问百泰生物药业有限公司!

站内搜索: 商品

您现在的位置:首页 >> 医患之家 >> 学术进展 >> 尼妥珠单抗联合化疗治疗晚期非小细胞肺癌(摘要)

尼妥珠单抗联合化疗治疗晚期非小细胞肺癌(摘要)

日期:2016年1月18日 21:37

   

Nimotuzumab in combination with chemotherapy in the patients with advanced non-small cell lung cancer

LI Lan-fang, ZHANG Hui-lai, QIAN Zheng-zi, QIU Li-hua, LI Wei, LIU Xian-ming, WANG Hua-qing.
    Department of Internal Medicine, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
[Abstract]
    Background: Nimotuzumab, a humanized anti-EGFR monoclonal antibody, has demonstrated well tolerate anti-cancer efficacy. Therefore, we designed the study for evaluate the role of Nimotuzumab in combination with chemotherapy in the patients with advanced non-small cell lung cancer (NSCLC).
    Material and Methods: A retrospective review of the clinical data of Cancer Hospital, Tianjin Medical University identified 37 NSCLC patients who received Nimotuzumab in combination with chemotherapy from January 2009 to October 2010. Of 37 patients, 12 patients were in stage IIIB, 25 patients in stage IV; 24 patients received platinum-based chemotherapy in combination with Nimotuzumab, 13 patients received nonplatinum-based chemotherapy in combination with Nimotuzumab; 10 patients administered Nimotuzumab plus chemotherapy as first-line regimen, 23 patients as second-line regimen, 4 patients as third-line regimen.
    Results: Of the 37 advanced NSCLC patients who received Nimotuzumab in combination with chemotherapy, the total number of chemotherapy were 137 cycles (mean 3.7 cycles); complete remission (CR) in one patient, partial remission (PR) in 9 patients, stable disease (SD) in 16 patients, progressive disease (PD) in 11 patients. The response rate (RR) was 27%,clinical benefit rate (CBR) was 70.3%. The main side effects were bone marrow depression and gastrointestinal reactions. Acneiform rash of grade I was found in one patient.
    Conclusions: The regimen of Nimotuzumab in combination with chemotherapy could improve response rate and was well tolerated in the patients with advanced non-small cell lung cancer.
[Key words] Nimotuzumab,  chemotherapy,  non-small cell lung cancer
 
Abstract number: E16-0505

所属类别: 学术进展

该资讯的关键词为:

在线留言
请留下您的宝贵意见或建议及联系方式(邮箱或电话),方便我们能及时回复您!
 
留言内容:
* 已输入字符:0
小于等于500字符
验证码:
   
联系我们
如果您有相关的合作意向,请您来电咨询或电邮cooperation@biotechplc.com !

泰欣生咨询热线:400-659-2330
公司总机:010-51571020
传 真:010-51571026
邮 编:100176
地 址:中国北京经济技术开发区荣京东街2号
学术微信:靶向治疗与精准医学 账号:zlbxzl